SynthesisTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014
Association of X-ray repair cross-complementing group 1 promoter rs3213245 polymorphism with lung cancer risk.
Synthesis in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Are SNP-Smoking Association Studies Needed in Controls? DNA Repair Gene Polymorphisms and Smoking Intensity.PloS one · 2015Article
- The relationship between genetic variants of XRCC1 gene and lung cancer susceptibility in Chinese Han population.Medical oncology (Northwood, London, England) · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
X-ray repair cross-complementing group 1 (XRCC1) is a major DNA repair protein in the base excision repair pathway. XRCC1 rs3213245 is a functional polymorphism in the XRCC1 gene promoter region which results in decreased DNA repair capacity. Previous studies investigating the association of XRCC1 rs3213245 polymorphism with lung cancer risk reported conflicting results. A meta-analysis of published studies was performed to provide a comprehensive assessment of the association. The pooled odds ratio (OR) with its 95% confidence interval (95% CI) was calculated to assess the association. Subgroup analysis was performed by ethnicity. Finally, six studies with a total of 3,208 cases and 3,505 control studies were included into our meta-analysis. The pooled results showed that there was a significant association between XRCC1 rs3213245 polymorphism and lung cancer risk (allele model: OR =1.31, 95% CI 1.13-1.51, P < 0.001; homozygote model: OR = 1.42, 95% CI 1.13-1.79, P = 0.003; recessive model: OR = 1.39, 95% CI 1.13-1.71, P = 0.002; dominant model: OR = 1.31, 95% CI 1.17-1.47, P < 0.001). Subgroup analysis by ethnicity showed that the association was still significant in both Asians (all P values less than 0.05) and Caucasians (recessive model: OR = 1.26, 95 % CI 1.01-1.59, P = 0.045). Thus, there is a significant association of XRCC1 rs3213245 polymorphism with lung cancer risk.
Indexed as
Identifiers
24470137What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.